Trial Profile
A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Apr 2024
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 25 Apr 2024 Planned initiation date changed from 30 Apr 2024 to 1 May 2024.
- 24 Apr 2024 Planned initiation date changed to 30 Apr 2024.
- 17 Apr 2024 Planned initiation date changed to 23 Apr 2024.